Advertisement
Screener

Lite Strategy, Inc. (LITS) Contract with Customer, Performance Obligation Satisfied in Previous Period

2.2 / 5 stars · 45/104 Roast Me

Lite Strategy, Inc. Contract with Customer, Performance Obligation Satisfied in Previous Period

Lite Strategy, Inc. (LITS) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $19.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-10.

Discontinued › Notes › Revenue from Contract with Customer

us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2020-11-10

  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-09-30 was $19.00M, a 413.51% increase year-over-year.
  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-06-30 was $12.30M, a 1437.50% increase year-over-year.
  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2020-03-31 was -$600.00K, a 400.00% decline year-over-year.
  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for the quarter ending 2019-12-31 was -$600.00K.
  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2020 was $14.80M, a 196.00% increase from fiscal 2019.
  • Lite Strategy, Inc. contract with customer, performance obligation satisfied in previous period for fiscal 2019 was $5.00M.
Period endContract with Customer, Performance Obligation Satisfied in Previous Period 3 monthContract with Customer, Performance Obligation Satisfied in Previous Period 6 monthContract with Customer, Performance Obligation Satisfied in Previous Period 9 monthContract with Customer, Performance Obligation Satisfied in Previous Period 12 month
2020-09-30$19.00M
10-Q · filed 2020-11-10
$31.30M
derived: sum of 2 quarters · filed 2020-11-10
$30.70M
derived: sum of 3 quarters · filed 2020-11-10
$30.10M
derived: sum of 4 quarters · filed 2020-11-10
2020-06-30$12.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09
$11.70M
derived: sum of 2 quarters · filed 2020-09-09
$11.10M
derived: sum of 3 quarters · filed 2020-09-09
$14.80M
10-K · filed 2020-09-09
2020-03-31-$600.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07
-$1.20M
derived: sum of 2 quarters · filed 2020-05-07
$2.50M
10-Q · filed 2020-05-07
$3.30M
derived: sum of 4 quarters · filed 2020-05-07
2019-12-31-$600.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06
$3.10M
10-Q · filed 2020-02-06
$3.90M
derived: sum of 3 quarters · filed 2020-02-06
$4.10M
derived: sum of 4 quarters · filed 2020-02-06
2019-09-30$3.70M
10-Q · filed 2019-11-07
$4.50M
derived: sum of 2 quarters · filed 2019-11-07
$4.70M
derived: sum of 3 quarters · filed 2019-11-07
2019-06-30$800.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-08-28
$1.00M
derived: sum of 2 quarters · filed 2019-08-28
$5.00M
10-K · filed 2019-08-28
2019-03-31$200.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-09
$4.20M
10-Q · filed 2019-05-09
2018-12-31$4.00M
10-Q · filed 2019-02-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
Xilio Therapeutics, Inc. (XLO)United States$0.052B
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38